Posterior Segment Company Showcase - Ohr pharmaceutical at OIS@AAO 2016. Presenter: Jason Slakter, CEO Powered by: Healthegy For more ophthalmology innovation Visit us at www.ois.net

1. Ophthalmology Innovation Summit
AAO 2016
October 13, 2016

2. Forward Looking Statement
This presentation contains forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. These forward looking
statements are made only as the date thereof, and Ohr undertakes no obligation to update or
revise the forward looking statement whether as a result of new information, future events or
otherwise. Our actual results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and uncertainties, including the future
success of our scientific studies, our ability to successfully develop products, rapid technological
change in our markets, changes in demand for our future products, legislative, regulatory and
competitive developments, the financial resources available to us, and general economic
conditions. For example, there can be no assurance that Ohr will be able to sustain operations for
expected periods. Shareholders and prospective investors are cautioned that no assurance of the
efficacy of pharmaceutical products can be claimed or assured until final testing; and no
assurance or warranty can be made that the FDA will approve final testing or marketing of any
pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports
discuss some of the important risk factors that may affect our business, results of operations and
financial condition. We disclaim any intent to revise or update publicly any forward-looking
statements for any reason.

3. Ohr Pharmaceutical Overview
• Ophthalmology-focused company with compelling early and late stage
pipeline
– Utilize innovative drug development strategies to meet patient needs in ocular disease
• Lead program – Squalamine lactate ophthalmic solution
– Phase 3 program in wet AMD actively enrolling
– Marked visual acuity benefit of combination therapy using topical Squalamine and
anti-VEGF injections in phase 2 study in wet AMD
• Additional indications for Squalamine
– Retinal vascular occlusive disease and diabetic retinopathy
– Visual acuity benefit seen in investigator sponsored trial in retinal vein occlusion
• Sustained release platform technology
– Four active internal programs
• Strong management team with deep expertise in ophthalmology drug
development

4. Unmet Need: A Topical Therapy That Improves and
Maintains VA Gains
Increase
Initial Visual
Acuity Gains
Maintain Long
Term Visual
Acuity Gains
MeanChangeinETDRSVisualAcuity(Letters)

5. Squalamine in the Wet AMD Armamentarium
VEGF-R1
Lucentis®
Genentech/Novartis
Avastin®
Genentech/Roche
RTH258
Alcon/Novartis
VEGF
VEGF-R2
Eylea®
Regeneron/Bayer
PDGF Fovista®
Ophthotech/Novartis
REG-2176
Regeneron
Squalamine
PDGF-R bFGF-R
Extracellular
Intracellular
DARPin
Allergan
Prevents downstream signaling of multiple angiogenic factors

6. Vascular Biology of CNV
12%
39%
49%
Incidence
Mixed Classic/Occult CNV
Occult CNV
Classic CNV
AJO 2014; 158: 769-779

7. Responsive to anti-VEGF therapy
• Reduction in leakage and at least partial vascular involution
• Located between the retina and retinal pigment epithelium (RPE)
• Vessels tend to be very rapidly growing and frequently manifest
symptoms early with leakage and bleeding which causes vision loss
• Mostly immature vessels with little pericyte coverage in the initial stages
of development
Classic Neovascularization

8. Primary target for combination therapy
• More resistant to anti-VEGF therapy – reduction in leakage but little
effect on anatomy
• Located beneath the RPE, just above the normal choroidal vascular
layers
• Vessels grow slowly and (as much as 30%) may be asymptomatic and
only later develop exudation and become clinically evident
• More mature vasculature and more pericyte coverage
Occult Neovascularization

9. Phase 2 Study in Wet AMD
Mandated Lucentis retreatment
SD-OCT evidence of:
• Any Retinal Cystic Changes
• Any Retinal Fluid
• Any Subretinal Fluid
• Meaningful RPE Elevation
Treatment-naïve patients with exudative AMD
• All lesion compositions (classic, mixed and occult only)
• Up to 12 disc areas in size
• VA 20/40 to 20/320
Lucentis® is a registered trademark of Genentech Inc.

10. Positive Visual Outcomes in Squalamine
Combination Therapy Driven by Occult CNV Size
• Occult CNV size at baseline directly correlates with week 36
visual acuity outcomes in Squalamine combination therapy
• This was independent of the presence/absence of classic CNV
• This relationship was not observed with ranibizumab
monotherapy treatment.
• Consistent positive visual acuity benefit with Squalamine
combination therapy in occult CNV < 10mm2 (~ 4 Disc Areas)
Occult CNV < 10mm2
Occult CNV > 10mm2

11. Positive Visual Outcomes in Occult CNV < 10mm2
Efficacy Consistent Through Month 9
Mean Change in Visual Acuity (Letters)
+5.3 letters
P = .038
MeanChangeinETDRSVisualAcuity(Letters)
Exploratory p-value

12. Positive Visual Outcomes in Occult CNV < 10mm2
Efficacy Consistent Through Month 9
Proportion with > 3 line VA Gain
54%
Benefit
ProportionofSubjectswith≥3LineGains

13. Improved Functional Vision Outcome
Better Final VA with Squalamine Combination Therapy
*One additional subject did not have a VA assessment at week 36
MeanETDRSVisualAcuity(Letters)

14. Phase 3 Study Design
Treatment-naïve patients with exudative AMD
• All lesion compositions (classic, mixed and occult only)
• Occult CNV (if present) <10 mm2
• VA 20/40 to 20/320
Primary Endpoint: Visual acuity gain at month 9

15. Squalamine Lactate Ophthalmic Solution
Summary
• Squalamine has the potential to be a convenient and cost-
effective therapy in retinal disease
• Indication in Exudative AMD
– Unmet need for improved vision beyond anti-VEGF monotherapy
– Strong phase 2 data supporting role of squalamine combination therapy in
providing clinically meaningful vision gains
• Use with Multiple Anti-VEGF Agents
– Combination effect with all current and future anti-VEGF agents
– Topical delivery adaptable for use with any anti-VEGF treatment
regimen/frequency
• Multiple back-of-the-eye indications
– Initial data in investigator led clinical trial evaluating retinal vein occlusion indicate
improved vision outcomes
– Suggests potential role in retinal vascular disease (RVO and DME)

16. Ohr Pharmaceutical Overview
• Ophthalmology-focused company with compelling early and late stage
pipeline
– Utilize innovative drug development strategies to meet patient needs in ocular disease
• Lead program – Squalamine lactate ophthalmic solution
– Phase 3 program in wet AMD actively enrolling
– Marked visual acuity benefit of combination therapy using topical Squalamine and
anti-VEGF injections in phase 2 study in wet AMD
• Additional indications for Squalamine
– Retinal vascular occlusive disease and diabetic retinopathy
– Visual acuity benefit seen in investigator sponsored trial in retinal vein occlusion
• Sustained release platform technology
– Four active internal programs
• Strong management team with deep expertise in ophthalmology drug
development

17. 2